U.S. consumers exploring noninvasive vagus nerve stimulation now have access to Nuropod, a wearable neurotechnology device built on over 10 years of research that supports the nervous system via gentle electrical pulses to the ear.
Sacramento, United States, September 10, 2026 /PressCable/ -- Nuropod is now available in the U.S., bringing its proprietary Auricular Vagal Neuromodulation Technology (AVNT™) waveform to consumers through a small wearable designed for noninvasive vagus nerve stimulation. The device clips onto the tragus, where the vagus nerve reaches the skin of the ear, and delivers gentle electrical pulses through that point.
More information is available at https://nuropod.com/pages/scientific-evidence
Amid growing consumer interest in wearable neurotechnology for stress management and sleep improvement, Nuropod was designed to address needs among consumers, particularly those seeking noninvasive approaches to nervous system support. Its scientific foundation includes 10+ years of R&D, 60+ completed studies, 100+ ongoing studies, and 150+ research partners.
The vagus nerve carries signals between the brain and organs, including the heart, lungs, and gut. It plays a central role in regulating stress, rest and recovery, the company explains. Developed by Parasym, Nuropod is built on the company's proprietary Auricular Vagal Neuromodulation Technology (AVNT™) and broader scientific research programme. Nuropod stimulates the vagus nerve through the ear using its proprietary technology, with the waveform designed to support the nervous system.
"People exploring vagus nerve stimulation should be able to understand both how a device works and the research behind its technology," a Nuropod representative said. "Our focus has been on building that evidence base while making the technology practical for everyday use."
Alongside its research focus, Nuropod is designed to make noninvasive vagus nerve stimulation accessible during ordinary daily life. It requires no surgery, clinic visit, prescription, or gel, and its compact design allows the device to fit into familiar routines without specialized skills.
Most people use the device for around 30 minutes, once or twice a day, while working, reading, or watching television. This approach, the company notes, allows consumers to incorporate wearable neurotechnology into activities they already perform throughout the day without requiring additional equipment.
Nuropod is FCC-compliant and is not a medical device.
Those interested can find additional information by visiting https://nuropod.com/pages/scientific-evidence
Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-designated risk device and is not intended to diagnose, treat, cure, or prevent any disease.
Contact Info:
Name: Victor Kho
Email: Send Email
Organization: Nuropod
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/
Source: PressCable
Release ID: 89202990
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.
